Trillium Therapeutics Inc (TRIL)

[jondoeuk]

I came across the following (the link appears broken): ''Dr. Akilov reported about a rapid response see with TTI-621 in a 67-year Sézary syndrome patient, who had multiple prior therapies and relapsed. After a single intratumoral injection (3 mg), the lesion showed regression on Day 3 and further reduction on Day 7. There was also a rapid reduction of SS tumour lymphocytes in peripheral blood from 56.2% at baseline to 26.9% on Day 3 and 5.8% on Day 5. The reduction of SS cells was accompanied by a transient increase in macrophages from 3.9% at baseline to 6.1% on Day 3. A significant increase in the percentage of NK cells and naïve CD8+ cells on Day 3, followed by a significant increase of CD4+ and CD8+ effector memory T cells on Day 5, was also observed after the injection. While the cutaneous tumour lesion regression was durable, most of the rapid immune cell changes in peripheral blood appeared transient, as SS cells, macrophage, CD8+ naïve T cell, and effector memory T cell levels all returned to baseline levels on Day 7. However, a single subcutaneous injection of PEGylated Interferon-a2a (90 ug) led to rapid reduction again of SS cells to 0.6% 7 days later and caused the complete regression of the cutaneous tumour lesion on Day 21. Such rapid response is usually not seen with PEG-IFNa2a alone.

The data, although in only 1 patient, suggest that the drug may have a rapid impact on both the local tumour lesion and the innate and adaptive immune response, suggesting that monotherapy is likely quite active in SS/CTCL. Although most of the systematic immune cell changes were transient, it may be due to the transient systematic PK profile of a single local injection of the drug with a half-life of around 4 days, which however could be improved with repeated injections. Moreover, the impact on both innate and adaptive immune cells seen after it was administered indicates promising combination opportunities with other immunotherapies in CTCL, as evidenced by the likely synergistic effects seen with PEG-IFNa2a in this SS patient.''

Here is the PR from Trillium http://trilliumtherapeutics.com/investors/news/Press-Release-Details/2017/Trillium-Therapeutics-TTI-621-Program-Featured-at-the-EORTC-CLTF-Cutaneous-Lymphoma-Conference/default.aspx